Browse All

Current Filters

CLEAR FILTER x

TITLE

Final results of the PANGAEA 2.0 study: Treatment benefits of fingolimod for active RRMS patients switching from other DMTs

Author:Weiss, Cordula   Ziemssen, Tjalf   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.009  

Author Institution:Novartis Pharma GmbH, Nuremberg, Germany  University Clinic Dresden, Dresden, Germany  

AMASIA study: Real world insights on the impact of early siponimod treatment on SPMS patients in Germany

Author:Hoffmann, Olaf   Schreiber, Herbert   Klotz, Luisa   Weber, Martin   Weiss, Cordula   Ziemssen, Tjalf   

Session Name:P8: MS Therapeutics 2  

Topic:MS and Inflammatory Disease  

Program Number:P8.013  

Author Institution:St.Josefs-Krankenhaus Potsdam, Potsdam, Germany  Neurological Practice Center Ulm, Ulm-Donau, Germany  Uniklinik Münster, Münster, Germany  University Medical Center Goettingen, Goettinger, Germany  Novartis Pharma GmbH, Nuremberg, Germany  University Clinic Dresden, Dresden, Germany  

Final results of the SPECTRE study: real-world data giving an insight into the treatment of migraine patients with erenumab in Germany

Author:Gaul, Charly   Koch, Mirja   Weiss, Cordula   

Session Name:P12: Headache: Towards Precision Medicine 2  

Topic:Headache  

Program Number:P12.011  

Author Institution:Headache Center Frankfurt, Frankfurt am Main, Germany, Frankfurt Am Main, Germany  Novartis AG, Basel, Switzerland  Novartis Pharma GmbH, Nuremberg, Germany